{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:19:25Z","timestamp":1790072365541,"version":"4.0.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72036-0","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:57:37Z","timestamp":1776430657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["NKG2A inhibition promotes NK cell-CD8+ T cell interactions to improve anticancer immunity in ovarian carcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7708-3169","authenticated-orcid":false,"given":"Tereza","family":"Lanickova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8956-0287","authenticated-orcid":false,"given":"Artemis","family":"Angelidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Hensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Vankerckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-9039","authenticated-orcid":false,"given":"Veronika","family":"Niederlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarka","family":"Vosahlikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Kasikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8840-8904","authenticated-orcid":false,"given":"Anna","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Zacharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0135-6637","authenticated-orcid":false,"given":"Christos","family":"Stekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9696-0445","authenticated-orcid":false,"given":"Barbora","family":"Tunkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Tomankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Glatzova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Moserova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Drozenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Cveckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2312-9165","authenticated-orcid":false,"given":"Thrinethra","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Laco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Ryska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Dundr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8900-8057","authenticated-orcid":false,"given":"Munachiso Iheme","family":"Ndukwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-4242","authenticated-orcid":false,"suffix":"Jr.","given":"Jiri","family":"Vachtenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-0874","authenticated-orcid":false,"given":"Linda","family":"Capkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-1678","authenticated-orcid":false,"given":"Marek","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal J.","family":"Halaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Rob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-5021","authenticated-orcid":false,"given":"Lize","family":"Allonsius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3373-1403","authenticated-orcid":false,"given":"Damya","family":"Laoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-1031","authenticated-orcid":false,"given":"Isabelle","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-8721","authenticated-orcid":false,"given":"Sandra","family":"Orsulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-3311","authenticated-orcid":false,"given":"Ondrej","family":"Stepanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-1942","authenticated-orcid":false,"given":"Francis","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-8500","authenticated-orcid":false,"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Spisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-479X","authenticated-orcid":false,"given":"Jitka","family":"Fucikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"72036_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"72036_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41571-024-00945-4","volume":"21","author":"S Banerjee","year":"2024","unstructured":"Banerjee, S. et al. Two decades of advances in clinical oncology - lessons learned and future directions. Nat. Rev. Clin. Oncol. 21, 771\u2013780 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72036_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72036_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","volume":"21","author":"J Budczies","year":"2024","unstructured":"Budczies, J. et al. Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat. Rev. Clin. Oncol. 21, 725\u2013742 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72036_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498\u2013512 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"72036_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","volume":"21","author":"E Ghisoni","year":"2024","unstructured":"Ghisoni, E. et al. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nat. Rev. Clin. Oncol. 21, 801\u2013817 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72036_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova, L. et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat. Commun. 15, 2528 (2024).","journal-title":"Nat. Commun."},{"key":"72036_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825\u20131863 (2024).","journal-title":"Cancer Cell"},{"key":"72036_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640\u2013656 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"72036_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf, N. K., Kissiov, D. U. & Raulet, D. H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat. Rev. Immunol. 23, 90\u2013105 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"72036_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong, L. et al. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol. Cancer 21, 206 (2022).","journal-title":"Mol. Cancer"},{"key":"72036_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederstadt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557\u2013575 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"72036_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington, N. D., Cursons, J. & Rautela, J. The cancer-natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437\u2013454 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"72036_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17644-0","volume":"11","author":"A Buque","year":"2020","unstructured":"Buque, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).","journal-title":"Nat. Commun."},{"key":"72036_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.immuni.2023.12.013","volume":"57","author":"E Narni-Mancinelli","year":"2024","unstructured":"Narni-Mancinelli, E., Berruyer, C. & Vivier, E. On blood and tissue-resident natural killer cells. Immunity 57, 6\u20138 (2024).","journal-title":"Immunity"},{"key":"72036_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100812","volume":"3","author":"N Lopes","year":"2022","unstructured":"Lopes, N. et al. Tissue-specific transcriptional profiles and heterogeneity of natural killer cells and group 1 innate lymphoid cells. Cell Rep. Med. 3, 100812 (2022).","journal-title":"Cell Rep. Med."},{"key":"72036_CR17","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","volume":"25","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet, L. et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat. Immunol. 25, 1474\u20131488 (2024).","journal-title":"Nat. Immunol."},{"key":"72036_CR18","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u201351 e20 (2023).","journal-title":"Cell"},{"key":"72036_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41580-018-0068-0","volume":"19","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L., Yamazaki, T. & Kroemer, G. Linking cellular stress responses to systemic homeostasis. Nat. Rev. Mol. Cell Biol. 19, 731\u2013745 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"72036_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","volume":"31","author":"J Fucikova","year":"2021","unstructured":"Fucikova, J., Spisek, R., Kroemer, G. & Galluzzi, L. Calreticulin and cancer. Cell Res. 31, 5\u201316 (2021).","journal-title":"Cell Res."},{"key":"72036_CR21","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2016-08-731737","volume":"128","author":"J Fucikova","year":"2016","unstructured":"Fucikova, J. et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood 128, 3113\u20133124 (2016).","journal-title":"Blood"},{"key":"72036_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u2013902 e21 (2019).","journal-title":"Cell"},{"key":"72036_CR23","doi-asserted-by":"publisher","unstructured":"Lischetti, U. et al. Ovarian cancer metastasis to the human omentum disrupts organ homeostasis and induces fundamental tissue reprogramming. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-025-67557-z (2025).","DOI":"10.1038\/s41467-025-67557-z"},{"key":"72036_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40933-8","volume":"9","author":"K de Jonge","year":"2019","unstructured":"de Jonge, K. et al. Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients. Sci. Rep. 9, 4487 (2019).","journal-title":"Sci. Rep."},{"key":"72036_CR25","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.ccell.2023.08.001","volume":"41","author":"G Escobar","year":"2023","unstructured":"Escobar, G. et al. Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell 41, 1662\u201379.e7 (2023).","journal-title":"Cancer Cell"},{"key":"72036_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211.e10 (2019).","journal-title":"Immunity"},{"key":"72036_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41368-022-00160-w","volume":"14","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. A comprehensive profile of TCF1(+) progenitor and TCF1(-) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. Int. J. Oral. Sci. 14, 8 (2022).","journal-title":"Int. J. Oral. Sci."},{"key":"72036_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/IGC.0000000000000888","volume":"27","author":"HC Bosmuller","year":"2017","unstructured":"Bosmuller, H. C. et al. CD56 (neural cell adhesion molecule) expression in ovarian carcinomas: association with high-grade and advanced stage but not with neuroendocrine differentiation. Int. J. Gynecol. Cancer 27, 239\u2013245 (2017).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"72036_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ygyno.2007.05.020","volume":"107","author":"Y Ohishi","year":"2007","unstructured":"Ohishi, Y. et al. CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol. Oncol. 107, 30\u201338 (2007).","journal-title":"Gynecol. Oncol."},{"key":"72036_CR30","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","volume":"116","author":"S Lopez-Verges","year":"2010","unstructured":"Lopez-Verges, S. et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116, 3865\u20133874 (2010).","journal-title":"Blood"},{"key":"72036_CR31","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","volume":"108","author":"S Lopez-Verges","year":"2011","unstructured":"Lopez-Verges, S. et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 108, 14725\u201314732 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72036_CR32","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-4175","volume":"25","author":"J Fucikova","year":"2019","unstructured":"Fucikova, J. et al. TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clin. Cancer Res. 25, 4820\u20134831 (2019).","journal-title":"Clin. Cancer Res."},{"key":"72036_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/2326-6066.CIR-21-0772","volume":"10","author":"JP Vayrynen","year":"2022","unstructured":"Vayrynen, J. P. et al. Spatial organization and prognostic significance of NK and NKT-like cells via multimarker analysis of the colorectal cancer microenvironment. Cancer Immunol. Res. 10, 215\u2013227 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"72036_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","volume":"19","author":"T Tsujikawa","year":"2017","unstructured":"Tsujikawa, T. et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 19, 203\u2013217 (2017).","journal-title":"Cell Rep."},{"key":"72036_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-422","volume":"13","author":"A Bachmayr-Heyda","year":"2013","unstructured":"Bachmayr-Heyda, A. et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients\u2013a study of the OVCAD consortium. BMC Cancer 13, 422 (2013).","journal-title":"BMC Cancer"},{"key":"72036_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/sj.bjc.6605274","volume":"101","author":"M Stumpf","year":"2009","unstructured":"Stumpf, M. et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br. J. Cancer 101, 1513\u20131521 (2009).","journal-title":"Br. J. Cancer"},{"key":"72036_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"72036_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb, J. R., Milne, K., Watson, P., Deleeuw, R. J. & Nelson, B. H. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20, 434\u2013444 (2014).","journal-title":"Clin. Cancer Res."},{"key":"72036_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","volume":"6","author":"I Truxova","year":"2018","unstructured":"Truxova, I. et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6, 139 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"72036_CR40","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"C Ovarian Tumor Tissue Analysis","year":"2017","unstructured":"Ovarian Tumor Tissue Analysis, C. et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 3, e173290 (2017).","journal-title":"JAMA Oncol."},{"key":"72036_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112808","volume":"28","author":"RH Mebane","year":"2025","unstructured":"Mebane, R. H. et al. Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures. iScience 28, 112808 (2025).","journal-title":"iScience"},{"key":"72036_CR42","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.ccell.2024.09.007","volume":"42","author":"IP MacFawn","year":"2024","unstructured":"MacFawn, I. P. et al. The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions. Cancer Cell 42, 1864\u201381.e5 (2024).","journal-title":"Cancer Cell"},{"key":"72036_CR43","doi-asserted-by":"publisher","unstructured":"Held, W., Siddiqui, I., Schaeuble, K., Speiser, D. E. Intratumoral CD8(+) T cells with stem cell-like properties: Implications for cancer immunotherapy. Sci. Transl. Med. 11 https:\/\/doi.org\/10.1126\/scitranslmed.aay6863 (2019).","DOI":"10.1126\/scitranslmed.aay6863"},{"key":"72036_CR44","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u201343.e13 (2018).","journal-title":"Cell"},{"key":"72036_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1917-0","volume":"17","author":"Y Zheng","year":"2019","unstructured":"Zheng, Y. et al. TNF-alpha-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. J. Transl. Med. 17, 165 (2019).","journal-title":"J. Transl. Med."},{"key":"72036_CR46","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J. Clin. Invest. 128, 4654\u20134668 (2018).","journal-title":"J. Clin. Invest."},{"key":"72036_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","volume":"25","author":"L Galluzzi","year":"2025","unstructured":"Galluzzi, L., Smith, K. N., Liston, A. & Garg, A. D. The diversity of CD8(+) T cell dysfunction in cancer and viral infection. Nat. Rev. Immunol. 25, 662\u2013679 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"72036_CR48","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","volume":"175","author":"N van Montfoort","year":"2018","unstructured":"van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744\u201355.e15 (2018).","journal-title":"Cell"},{"key":"72036_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler, A. & Vignali, D. A. A. T cell exhaustion. Annu. Rev. Immunol. 42, 179\u2013206 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"72036_CR50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72036_CR51","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dominguez, R. & Silva-Santos, B. The emerging roles of gammadelta T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72036_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Control of metastasis by NK cells. Cancer Cell 32, 135\u2013154 (2017).","journal-title":"Cancer Cell"},{"key":"72036_CR53","doi-asserted-by":"publisher","unstructured":"Petroni, G. et al. IL-17A-secreting gammadelta T cells promote resistance to CDK4\/CDK6 inhibitors in HR(+)HER2(-) breast cancer via CX3CR1(+) macrophages. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-025-01007-z (2025).","DOI":"10.1038\/s43018-025-01007-z"},{"key":"72036_CR54","doi-asserted-by":"publisher","unstructured":"Patel, S. P. et al. Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J. Immunother. Cancer 12 https:\/\/doi.org\/10.1136\/jitc-2023-007340 (2024).","DOI":"10.1136\/jitc-2023-007340"},{"key":"72036_CR55","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 13, 2394\u20132411 (2023).","journal-title":"Cancer Discov."},{"key":"72036_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko, N. A., Zhigarev, D. & Campbell, K. S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat. Rev. Drug Discov. 21, 559\u2013577 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72036_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","volume":"41","author":"O Kyrysyuk","year":"2023","unstructured":"Kyrysyuk, O. & Wucherpfennig, K. W. Designing cancer immunotherapies that engage T cells and NK cells. Annu. Rev. Immunol. 41, 17\u201338 (2023).","journal-title":"Annu. Rev. Immunol."},{"key":"72036_CR58","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","journal-title":"J. Clin. Oncol."},{"key":"72036_CR59","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","volume":"20","author":"F Barlesi","year":"2024","unstructured":"Barlesi, F. et al. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 20, 2137\u20132147 (2024).","journal-title":"Future Oncol."},{"key":"72036_CR60","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman, W. H. et al. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity 56, 2254\u20132269 (2023).","journal-title":"Immunity"},{"key":"72036_CR61","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"72036_CR62","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1182\/blood-2008-02-135871","volume":"112","author":"S Agaugue","year":"2008","unstructured":"Agaugue, S., Marcenaro, E., Ferranti, B., Moretta, L. & Moretta, A. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 112, 1776\u20131783 (2008).","journal-title":"Blood"},{"key":"72036_CR63","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.4049\/jimmunol.173.6.3716","volume":"173","author":"A Zingoni","year":"2004","unstructured":"Zingoni, A. et al. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 173, 3716\u20133724 (2004).","journal-title":"J. Immunol."},{"key":"72036_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1074-7613(03)00264-4","volume":"19","author":"R Mocikat","year":"2003","unstructured":"Mocikat, R. et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561\u2013569 (2003).","journal-title":"Immunity"},{"key":"72036_CR65","doi-asserted-by":"publisher","unstructured":"Peng, P. et al. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-gamma to modulate antitumor T-cell response after cryo-thermal therapy. J. Immunother. Cancer 10 https:\/\/doi.org\/10.1136\/jitc-2022-005769 (2022).","DOI":"10.1136\/jitc-2022-005769"},{"key":"72036_CR66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.celrep.2019.12.034","volume":"30","author":"E Maniati","year":"2020","unstructured":"Maniati, E. et al. Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment. Cell Rep. 30, 525\u201340.e7 (2020).","journal-title":"Cell Rep."},{"key":"72036_CR67","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s42003-023-05529-z","volume":"6","author":"DP Cook","year":"2023","unstructured":"Cook, D. P. et al. Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer. Commun. Biol. 6, 1152 (2023).","journal-title":"Commun. Biol."},{"key":"72036_CR68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2767-9764.CRC-22-0017","volume":"2","author":"GM Rodriguez","year":"2022","unstructured":"Rodriguez, G. M. et al. The tumor immune profile of murine ovarian cancer models: an essential tool for ovarian cancer immunotherapy research. Cancer Res. Commun. 2, 417\u2013433 (2022).","journal-title":"Cancer Res. Commun."},{"key":"72036_CR69","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"72036_CR70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga, A. et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol. Oncol. 152, 243\u2013250 (2019).","journal-title":"Gynecol. Oncol."},{"key":"72036_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44789-z","volume":"15","author":"I Dean","year":"2024","unstructured":"Dean, I. et al. Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nat. Commun. 15, 683 (2024).","journal-title":"Nat. Commun."},{"key":"72036_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997806","volume":"13","author":"D Mele","year":"2022","unstructured":"Mele, D. et al. Impaired intratumoral natural killer cell function in head and neck carcinoma. Front. Immunol. 13, 997806 (2022).","journal-title":"Front. Immunol."},{"key":"72036_CR73","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","volume":"127","author":"JA Wagner","year":"2017","unstructured":"Wagner, J. A. et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J. Clin. Invest. 127, 4042\u20134058 (2017).","journal-title":"J. Clin. Invest."},{"key":"72036_CR74","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm.4278","volume":"23","author":"SQ Crome","year":"2017","unstructured":"Crome, S. Q. et al. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat. Med. 23, 368\u2013375 (2017).","journal-title":"Nat. Med."},{"key":"72036_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s40425-018-0433-8","volume":"6","author":"SQ Crome","year":"2018","unstructured":"Crome, S. Q. & Ohashi, P. S. Immunoregulatory functions of innate lymphoid cells. J. Immunother. Cancer 6, 121 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"72036_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41590-022-01127-z","volume":"23","author":"N Jacquelot","year":"2022","unstructured":"Jacquelot, N., Seillet, C., Vivier, E. & Belz, G. T. Innate lymphoid cells and cancer. Nat. Immunol. 23, 371\u2013379 (2022).","journal-title":"Nat. Immunol."},{"key":"72036_CR77","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(17)30438-2","volume":"18","author":"B O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan, B. et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 18, 849\u2013851 (2017).","journal-title":"Lancet Oncol."},{"key":"72036_CR78","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I Vazquez-Garcia","year":"2022","unstructured":"Vazquez-Garcia, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778\u2013786 (2022).","journal-title":"Nature"},{"key":"72036_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim, N. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 11, 2285 (2020).","journal-title":"Nat. Commun."},{"key":"72036_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00632-7","volume":"12","author":"HY Ju","year":"2024","unstructured":"Ju, H. Y. et al. Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer. Biomark. Res. 12, 80 (2024).","journal-title":"Biomark. Res."},{"key":"72036_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"M De Zuani","year":"2024","unstructured":"De Zuani, M. et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat. Commun. 15, 4388 (2024).","journal-title":"Nat. Commun."},{"key":"72036_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37905-y","volume":"14","author":"ER Parra","year":"2023","unstructured":"Parra, E. R. et al. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat. Commun. 14, 2364 (2023).","journal-title":"Nat. Commun."},{"key":"72036_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05035-8","volume":"22","author":"J Monkman","year":"2024","unstructured":"Monkman, J. et al. Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging. J. Transl. Med. 22, 239 (2024).","journal-title":"J. Transl. Med."},{"key":"72036_CR84","doi-asserted-by":"publisher","unstructured":"Lanickova, T. et al. Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1594 (2024).","DOI":"10.1158\/1078-0432.CCR-24-1594"},{"key":"72036_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"72036_CR86","doi-asserted-by":"publisher","unstructured":"Hensler, M. et al. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. J. Immunother. Cancer 8 https:\/\/doi.org\/10.1136\/jitc-2020-000979 (2020).","DOI":"10.1136\/jitc-2020-000979"},{"key":"72036_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"72036_CR88","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat. Protoc. 20, 180\u2013219 (2025).","journal-title":"Nat. Protoc."},{"key":"72036_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"72036_CR90","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41587-021-00830-w","volume":"40","author":"DM Cable","year":"2022","unstructured":"Cable, D. M. et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat. Biotechnol. 40, 517\u2013526 (2022).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72036-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72036-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:19:39Z","timestamp":1781741979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72036-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72036"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72036-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.Ry. declare advisory services and invited lectures for Amgen, AstraZeneca, BMS, Eli-Lilly, Janssen-Cilag, MSD, Roche. L.Ga. is\/has been holding research contracts with Lytix Biopharma, Onxeo and Promontory, has received consulting\/advisory honoraria from Boehringer Ingelheim, AbbVie, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Sotio Biotech a.s., Promontory, Noxopharm and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. R.Sp. is a minority shareholder of Sotio Biotech a.s. T.La., A. An., M.He., A. Va., S.Vo., L.Ka., A.Bo., E.Za., Ch.St., B. Tu., J. To., D.Gl., I. Mo., B.Cv., R.Sp. and J.Fu. are full-time employess of Sotio Biotech a.s. All other authors have no conflicts to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5366"}}